Stocks · Theme
Cardiovascular therapeutics stocks · 5 research notes
5 Cardiovascular therapeutics stocks moving on the same story, each with a dated research note: thesis, kill line and next catalyst.
Active themeTracked as of 11 November 2026.
All 5 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksKNSAKiniksa Pharmaceuticals International, plcfreshMediumKiniksa Pharmaceuticals' third 2026 ARCALYST guidance raise, to $1.045–1.050 billion, still anchors the case after the shares eased to $95.02 on 10 November 2026 from a record $98.76. Fourth-quarter sales in the early-2027 report settle…EWTXEdgewise Therapeutics, Inc.MediumEdgewise Therapeutics now trades on unconfirmed takeover reports on top of FDA-cleared Phase 3 plans for its heart drug EDG-7500 and $1.74 billion of cash. A confirmed deal or the STRATUS-HCM trial start, due by 31 December 2026, decides…LQDALiquidia CorporationMediumLiquidia's 13 October 2026 settlement with United Therapeutics keeps its PAH drug YUTREPIA on the market at a net cost of $380.7 million; the 10 November 2026 Q3 report shows whether sales can keep growing once PH-ILD leaves the label.CRDLCardiol Therapeutics Inc.LowCardiol Therapeutics is more likely to lag than lead the S&P 500: its one decisive event, the MAVERIC Phase III topline, is guided for mid-2027, and a US$75 million at-the-market stock program opened on 3 November 2026. The Q3 report,…IKTInhibikase Therapeutics, Inc.freshLowInhibikase Therapeutics' IKT-001 for pulmonary arterial hypertension is funded, with $193.3M cash on 30 September 2026, but dilution and warrant-dependent runway weigh on shares at $1.55; 2027 interim safety data is next.